Skip to main content
HR 4116 115th Congress House

Transparent Drug Pricing Act of 2017

Official title: To amend the Public Health Service Act to require reporting by drug manufacturers to increase transparency in drug pricing, and for other purposes.

Introduced: April 11, 2018 Introduced by: Doggett, Lloyd Democratic · Texas See on congress.gov
Health Accounting and auditingBusiness recordsCongressional oversightCorporate finance and management
More subjectsShow fewer subjects
Government studies and investigationsHealth care costs and insuranceInflation and pricesIntellectual propertyMarketing and advertisingMedical researchPrescription drugsProduct development and innovationResearch administration and fundingResearch and developmentSmall businessWages and earnings
Sign in to write a letter Sign in to watch
This bill died when the 115th Congress ended
It never became law before the 115th Congress (2017–2018) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 27, 2017
Referred to the Subcommittee on Health.
Oct 25, 2017
Referred to the House Committee on Energy and Commerce.
Oct 25, 2017
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 27, 2017

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Transparent Drug Pricing Act of 2017

This bill requires drug manufacturers to report specified financial and sales information, including drug pricing, tax credit, and patent information; violations are subject to civil penalties.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 24
All 24 Democratic 22
D
Takano, Mark
California · Sep 4, 2018
 D
Waters, Maxine
California · Sep 4, 2018
 D
Cleaver, Emanuel
Missouri · Jul 19, 2018
 D
DeSaulnier, Mark
California · Jul 19, 2018
 D
Gonzalez, Vicente
Texas · Jul 19, 2018
 D
Green, Al
Texas · Jul 19, 2018
GUTIERREZ, LUIS
· Jul 19, 2018
 D
Moore, Gwen
Wisconsin · Jul 19, 2018
Shea-Porter, Carol
· Jul 19, 2018
 D
Thompson, Bennie G.
Mississippi · Jul 19, 2018
 D
Velázquez, Nydia M.
New York · Jul 19, 2018
 D
Khanna, Ro
California · Apr 11, 2018
 D
Norton, Eleanor Holmes
District of Columbia · Apr 11, 2018
 D
Pingree, Chellie
Maine · Jan 20, 2018
 D
Chu, Judy
California · Jan 18, 2018
 D
Johnson, Henry C. "Hank"
Georgia · Jan 18, 2018
 D
Jayapal, Pramila
Washington · Nov 28, 2017
 D
Welch, Peter
Vermont · Nov 28, 2017
 D
Cohen, Steve
Tennessee · Oct 25, 2017
 D
DeLauro, Rosa L.
Connecticut · Oct 25, 2017
 D
Kaptur, Marcy
Ohio · Oct 25, 2017
 D
Nadler, Jerrold
New York · Oct 25, 2017
 D
Pocan, Mark
Wisconsin · Oct 25, 2017
 D
Raskin, Jamie
Maryland · Oct 25, 2017
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4116: Transparent Drug Pricing Act of 2017. 115th Congress. Open America. https://openamerica.io/bill/115-HR-4116/
MLA
"H.R. 4116: Transparent Drug Pricing Act of 2017." 115th Congress, 2026, Open America, https://openamerica.io/bill/115-HR-4116/.
Bluebook (legal)
H.R. 4116, 115th Cong. (2026), https://openamerica.io/bill/115-HR-4116/.
Markdown link
[H.R. 4116: Transparent Drug Pricing Act of 2017](https://openamerica.io/bill/115-HR-4116/)
Report a problem